Table 1.
Demographics and clinical characteristics of cohorts from phase I, phase II and antibiotics subgroup for CDI GWAS.
| Phase I (11,786) | Phase II (3,518) | Antibiotic subgroup (3,753) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Case (946) | Control (10840) | P value | Case (214) | Control (3304) | P value | Case (587) | Control (3166) | P value | |
| Male Sex, n (%) | 414 (43.8) | 4126 (38.1) | 0.001 | 68 (31.8) | 1079 (32.7) | 0.79 | 245 (41.7) | 1040 (32.8) | 3.76E-05 |
| Index age, mean ± SD | 60.3 ± 17.7 | 59.0± 19.2 | 0.041 | 52.7 ± 18.0 | 49.0 ± 18.7 | 0.005 | 61.0 ± 17.1 | 55.6 ± 18.9 | 7.67E-11 |
| Antibiotics, n (%) | 480 (50.7) | 2294 (21.2) | 5.58E-94 | 107 (50) | 872 (26.4) | 8.14E-14 | / | / | / |
| Chemotherapy, n (%) | 88 (9.3) | 998 (9.2) | 0.922 | 15 (7) | 454 (13.7) | 0.005 | 60 (10.2) | 535 (16.9) | 4.74E-05 |
| PPI, n (%) | 398 (42.1) | 2944 (27.2) | 1.68E-22 | 67 (31.3) | 818 (24.8) | 0.032 | 262 (44.6) | 1175 (37.1) | 0.001 |
| Steroid, n (%) | 288 (30.6) | 2137 (19.7) | 2.50E-15 | 51 (23.8) | 691 (20.9) | 0.311 | 196 (33.4) | 1027 (32.4) | 0.651 |
| Anti-TNF, n (%) | 16 (1.7) | 75 (0.7) | 0.001 | 1 (0.5) | 14 (0.4) | 0.924 | 3 (0.5) | 15 (0.5) | 0.904 |
| Transplant, n (%) | 52 (5.5) | 432 (4.0) | 0.023 | 3 (1.4) | 75 (2.3) | 0.403 | 22 (3.7) | 127 (4) | 0.764 |
| IBD, n (%) | 81 (8.6) | 218 (2.0) | 1.03E-34 | 30 (14.0) | 60 (1.8) | 6.15E-28 | 36 (6.1) | 59 (1.9) | 1.46E-09 |
| T2DM, n (%) | 370 (39.3) | 3685 (34.0) | 0.001 | 42 (19.6) | 630 (19.1) | 0.84 | 224 (38.2) | 1009 (31.9) | 0.003 |
ANOVA was adopted to test the significance of index age and Chi-square test was adopted to test all other variables. IBD, Inflammatory Bowel Disease; PPI, proton pump inhibitors; TNF, tumor necrosis factor; T2DM, Type 2 Diabetes; HIV, human immunodeficiency virus.